Objective: To retrospectively evaluate the use and adverse effects of oral azithromycin prescribed in guinea pigs and chinchilla patients.
Methods: The medical record database of a veterinary teaching hospital was searched from 2009 to 2025 for records of guinea pigs or chinchillas that were prescribed oral azithromycin. Data reviewed included age, weight, indicated use, azithromycin dose, treatment duration, follow-up, and potential adverse effects within 4 weeks of administration.
Results: 101 guinea pigs and 30 chinchillas were included in this study. The most common indications for treatment were otitis media in guinea pigs and dental disease in chinchillas. The median azithromycin dose was 30 mg/kg, PO, every 24 hours, in both species. Minor adverse effects occurred in 10% of guinea pigs with follow-up information available (6 of 58), with hyporexia being reported in all 6 cases. In addition, in 3 of these cases, diarrhea and weight loss were reported. One guinea pig (1 of 58) developed severe adverse effects (typhlitis) during their third course of azithromycin and was euthanized. There were no documented adverse effects of azithromycin prescribed in chinchillas within 4 weeks of administration.
Conclusions: In guinea pigs prescribed oral azithromycin, 10% (6 of 58) had minor adverse effects, while 1 guinea pig (1 of 58) developed severe adverse effects and was euthanized during their third course of azithromycin. There were no documented adverse effects of oral azithromycin prescribed to chinchillas.
Clinical relevance: Based on this retrospective study, orally administered azithromycin appears suitable for clinical use in guinea pigs and chinchillas.
扫码关注我们
求助内容:
应助结果提醒方式:
